Imaging in Inflammatory Heart Diseases linked to autoimmune disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

ICARDs cover cardiovascular involvement in autoimmune and inflammatory diseases. The study collects and analyzes imaging data from adults referred for CMR or nuclear imaging to understand how often heart involvement is present and how imaging findings relate to diagnosis. It uses observational methods to describe imaging prevalence and potential prognostic signals. The goal is to improve diagnostic clarity for conditions such as myocarditis, pericarditis, vasculitis, and connective tissue diseases with heart involvement. The investigation is conducted in a real-world clinical setting across a Parisian institutional network.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years
2. Ability to provide informed non-opposition
3. Referred for a CMR and/or nuclear imaging exam

AND a suspicion of one of the following ICARDs :

1. Suspected Myocarditis (acute or chronic, and whatever the aetiologies)
2. Suspected Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA)
3. Suspected Tako-Tsubo
4. Suspected Pericarditis (acute or chronic, and whatever the aetiologies)
5. Suspected Connective tissue disease with cardiovascular involvement:

   * Systemic sclerosis
   * Systemic lupus erythematosus
   * Antiphospholipid syndrome
   * Idiopathic inflammatory myopathies
   * Rheumatoid arthritis, spondylarthritis
6. Suspected Vasculitis with cardiovascular involvement:

   * Small-vessel vasculitis (ANCA…)
   * Large vessel vasculitis (Behcet disease, Takayasu…)
7. Suspected Inflammatory disease with cardiovascular involvement:

   * Sarcoidosis
   * Still disease

Exclusion Criteria:

1. Inability to provide non-opposition
2. History of heart transplant

Where it's running

• Assistance Publique Hôpitaux de Paris, Paris, île de France 75010
  Paris, France Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry and biorepository for rheumatic diseases

  This study is collecting samples and health information from adults with rheumatic diseases at Yale clinics to help researchers learn more about these conditions and improve future treatments.

  Recruiting Yale University · New Haven, Connecticut · NCT04402086

• Test of HBM7020 in healthy adults and adults with autoimmune diseases

  This first-in-human study tests whether HBM7020 is safe and how it acts in the body for people with autoimmune diseases like RA, SLE, Sjögren's, and SSc compared with healthy volunteers.

  Recruiting Phase 1 Otsuka Pharmaceutical Development & Commercialization, Inc. · Brisbane, Queensland · NCT07649265

• Anti-CD19/BCMA universal CAR-T cell therapy for refractory autoimmune diseases

  This will try anti-CD19/BCMA universal CAR-T cell therapy in adults with refractory rheumatoid arthritis, dermatomyositis, systemic lupus, or systemic sclerosis to see if it is safe and can control their disease.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07558850

• Immun4Cure Cohort of Autoimmune Diseases

  A long-term, 500-person database and biobank is being built to study autoimmune diseases like RA, SLE, and scleroderma, plus healthy adults, using deep profiling and regular follow-ups over five years.

  Recruiting University Hospital, Montpellier · Montpellier · NCT07515638

• AZD0120 CD19/BCMA CAR T-cell therapy for systemic sclerosis, inflammatory myopathies, and difficult-to-treat rheumatoid arthritis

  This trial will try a dual-targeting CD19/BCMA CAR T-cell treatment (AZD0120) in adults with systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis to see if it is safe and well tolerated.

  Recruiting at 5 sites Phase 1/2 AstraZeneca · Tucson, Arizona and 26 other locations · NCT07295847

• Anti-CD19/BCMA U CAR-T cell therapy for relapsed or refractory autoimmune diseases

  This pilot will test whether anti-CD19/BCMA U CAR-T cells can help adults with relapsed or refractory autoimmune diseases such as SLE, systemic sclerosis, Sjögren's syndrome, and rheumatoid arthritis.

  Recruiting Early Phase 1 Changhai Hospital · Shanghai · NCT07246096

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.